Return to homepagePandemic Pact

The role of antihypertensive drugs in Covid-19

Grant number: Unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Known Financial Commitments (USD)

    $428,400

  • Funder

    FWF

  • Principal Investigator

    Oliver Langer

  • Research Location

    Austria

  • Lead Research Institution

    Department of Clinical Pharmacology, Medical University of Vienna

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Do antihypertensive drugs have an impact on SARS-CoV-2 infection? Since the pandemic began, researchers have been using a variety of methods in an attempt to definitively determine the role of the ACE2 enzyme, but so far without success. This enzyme is of interest because it allows the coronavirus to enter and infect healthy cells. Pharmacist Oliver Langer and his group plan to use the FWF urgent funding to develop a method that can determine the concentration of ACE2 in tissue using positron emission tomography (PET) with a radiolabelled substance, thus enabling us to better assess the impact of antihypertensives. The method and the results derived from it will make an important contribution to the development of new COVID-19 drugs.